Risk of Bleeding After Percutaneous Endoscopic Gastrostomy in Patients Using Antithrombotic Drugs.


Journal

Surgical laparoscopy, endoscopy & percutaneous techniques
ISSN: 1534-4908
Titre abrégé: Surg Laparosc Endosc Percutan Tech
Pays: United States
ID NLM: 100888751

Informations de publication

Date de publication:
01 10 2023
Historique:
received: 04 01 2023
accepted: 02 06 2023
pubmed: 31 7 2023
medline: 31 7 2023
entrez: 31 7 2023
Statut: epublish

Résumé

The rate of using antithrombotic (AT) drugs is frequently high in patients who require percutaneous endoscopic gastrostomy (PEG). The aim of this study was to determine whether the risk of bleeding after PEG increases in patients whose AT drugs were discontinued according to the European Society Gastrointestinal Endoscopy guidelines (warfarin for 5 d, low molecular weight heparin for 24 h, DOAC for 3 d, and clopidogrel for 7 d). Data from 243 patients, who underwent PEG tube placement and received AT drugs and 206 patients who did not between 2018 and 2021 in our hospital, were evaluated retrospectively. Bleeding was defined as requiring blood transfusion, hematemesis and/or melena, decreased hemoglobin, or bleeding from PEG. A total of 243 (54.1%) patients (121 (49.7%), women, mean age (75.7 y) who underwent PEG and received AT drugs, and 206 (45.9%) patients who did not (92 (44.6%), women, mean age (63.15 y). The medications and bleeding rates of the patients are given in Table 1. The rate of bleeding in patients using AT medication was significantly higher than that in patients not using medication (Table 2) ( P = 0.007). When the AT drugs were compared among themselves, the bleeding risk did not differ. Bleeding was detected in 10 patients with bleeding from the PEG tube in 4 with melena. Bleeding detected in 14 patients was controlled with adrenaline injections. None of the patients required transfusion or repeat endoscopies. No bleeding-related deaths were reported. Even if patients receiving AT drugs are treated as recommended by international guidelines, it should be kept in mind that bleeding may occur after PEG, and the patients should be followed accordingly.

Sections du résumé

BACKGROUND
The rate of using antithrombotic (AT) drugs is frequently high in patients who require percutaneous endoscopic gastrostomy (PEG). The aim of this study was to determine whether the risk of bleeding after PEG increases in patients whose AT drugs were discontinued according to the European Society Gastrointestinal Endoscopy guidelines (warfarin for 5 d, low molecular weight heparin for 24 h, DOAC for 3 d, and clopidogrel for 7 d).
PATIENTS AND METHODS
Data from 243 patients, who underwent PEG tube placement and received AT drugs and 206 patients who did not between 2018 and 2021 in our hospital, were evaluated retrospectively. Bleeding was defined as requiring blood transfusion, hematemesis and/or melena, decreased hemoglobin, or bleeding from PEG.
RESULTS
A total of 243 (54.1%) patients (121 (49.7%), women, mean age (75.7 y) who underwent PEG and received AT drugs, and 206 (45.9%) patients who did not (92 (44.6%), women, mean age (63.15 y). The medications and bleeding rates of the patients are given in Table 1. The rate of bleeding in patients using AT medication was significantly higher than that in patients not using medication (Table 2) ( P = 0.007). When the AT drugs were compared among themselves, the bleeding risk did not differ. Bleeding was detected in 10 patients with bleeding from the PEG tube in 4 with melena. Bleeding detected in 14 patients was controlled with adrenaline injections. None of the patients required transfusion or repeat endoscopies. No bleeding-related deaths were reported.
CONCLUSION
Even if patients receiving AT drugs are treated as recommended by international guidelines, it should be kept in mind that bleeding may occur after PEG, and the patients should be followed accordingly.

Identifiants

pubmed: 37523586
doi: 10.1097/SLE.0000000000001210
pii: 00129689-202310000-00018
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

540-542

Informations de copyright

Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.

Déclaration de conflit d'intérêts

The authors declare no conflicts of interest.

Références

DiSario JA. Endoscopic approaches to enteral nutritional support. Best Pract Res Clin Gastroenterol. 2006;20:605–630.
Maple JT, Peterson BT, Gostout CJ, et al. Direct percutaneous endoscopic jejunostomy: outcomes in 307 consecutive attempts. Am J Gastroenterol. 2005;100:2681–2688.
Rahnemai-Azar RAA, Naghshizadian R, Rahnemaiazar AA, et al. Percutaneous endoscopic gastrostomy: indications, technique, complications and management. World J Gastroenterol. 2014;20:7739–7751.
Veitch AM, Radaelli F. Endoscopy in patients on antiplatelet or anticoagulant therapy: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guideline update. Endoscopy. 2021;48:385–402.
Cotton P, Williams C. Practical gastrointestinal endoscopy. 4th ed. Oxford: Alden Press; 1996:168.
Ponsky JL, Gauderer MW. Percutaneous endoscopic gastrostomy: a nonoperative technique for feeding gastrostomy. Gastrointest Endosc. 1981;27:9–11.
Kirby DF, Delegge MH, Fleming CR. American Gastroenterological Association technical review on tube feeding for enteral nutrition. Gastroenterology. 1995;108:1282–1301.
Rosenberger LH, Newhook T, Schirmer B, et al. Late accidental dislodgement of a percutaneous endoscopic gastrostomy tube: an underestimated burden on patients and the health care system. Surg Endosc. 2011;25:3307–3311.
Schapiro GD, Edmundowicz SA. Complications of percutaneous endoscopic gastrostomy. Gastrointest Endosc Clin N Am. 1996;6:409–422.
Veitch AM, Vanbiervliet G, Gershlick AH, et al. Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines. Endoscopy. 2016;48:1–18.
Singh D, Laya AS, Vaidya OU, et al. Risk of bleeding after percutaneous endoscopic gastrostomy (PEG). Dig Dis Sci. 2011;57:973–980.
Ruthmann O, Seitz A, Richter S, et al. Percutaneous endoscopic gastrostomy. Complications with and without anticoagulation. Chirurg. 2010;91:247–254.

Auteurs

Yavuz Emre Parlar (YE)

Department of Gastroenterology, Hacettepe University, Ankara, Turkey.

Fuad Mustafayev (F)

Department of Gastroenterology, Aegean Hospital, Baku, Azerbaijan.

Cavanşir Vahabov (C)

Department of Gastroenterology, Aegean Hospital, Baku, Azerbaijan.

Tevhide Şahin (T)

Department of Gastroenterology, Hacettepe University, Ankara, Turkey.

Sabir İsrafilov (S)

Department of Gastroenterology, Hacettepe University, Ankara, Turkey.

Onur Keskin (O)

Department of Gastroenterology, Hacettepe University, Ankara, Turkey.

Hatice Yasemin Balaban (HY)

Department of Gastroenterology, Hacettepe University, Ankara, Turkey.

Taylan Kav (T)

Department of Gastroenterology, Hacettepe University, Ankara, Turkey.

Erkan Parlak (E)

Department of Gastroenterology, Hacettepe University, Ankara, Turkey.

Halis Şimşek (H)

Department of Gastroenterology, Hacettepe University, Ankara, Turkey.

Bülent Sivri (B)

Department of Gastroenterology, Hacettepe University, Ankara, Turkey.

Classifications MeSH